| Name | Title | Contact Details |
|---|
NeuBase is developing ultra precision genetic medicines targeting rare, monogenic diseases, therapeutic candidates for the treatment of myotonic dystrophy type 1 (DM1), Huntington`s disease (HD), and cancer-driving point mutations in KRAS G12V and G12D, which are involved in many tumor types and have historically been “undruggable.” for which there are no approved therapies, as well as more common genetic disorders, including cancers that are resistant to current therapeutic approaches. NeuBase`s pipeline includes
Honson Industries Ltd is a Markham, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Laboratory Technologies is a Maple Park, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Cellular Engineering Technologies is a Iowa City, IA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
As America’s largest independent cardiac care practice, CCP is home to the most experienced cardiologists in the Philadelphia region.